Format

Send to

Choose Destination
Arch Gynecol Obstet. 2018 Mar;297(3):749-756. doi: 10.1007/s00404-018-4658-z. Epub 2018 Jan 16.

Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma.

Author information

1
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.
2
Advanced Technology Center, Medical Solution Segment, LSI Medience Corporation, Tokyo, Japan.
3
Department of Obstetrics and Gynecology, Tokai University School of Medicine, Shimokasuya, Isehara, Kanagawa, 2591193, Japan.
4
Division of Basic Medical Science and Molecular Medicine, Department of Molecular Life Science, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
5
Department of Pathology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
6
Department of Obstetrics and Gynecology, Tokai University School of Medicine, Shimokasuya, Isehara, Kanagawa, 2591193, Japan. mmikami@is.icc.u-tokai.ac.jp.

Abstract

PURPOSE:

Fully sialylated alpha-chain of complement 4-binding protein (A2160) is a member of the glycoprotein family and has recently been identified as a diagnostic biomarker for epithelial ovarian cancer. This study examined the utility of A2160 as a prognostic biomarker for this disease.

METHODS:

This is a retrospective analysis of prospectively collected plasma samples from 93 women with stage I-IV epithelial ovarian cancer who underwent primary cytoreductive surgery between 2009 and 2014. Pretreatment A2160 levels were correlated to clinico-pathological factors and survival outcome.

RESULTS:

Women with advanced-stage disease had significantly higher 2160 levels compared to those with early stage disease (stage I-II versus III-IV, median 2.17-2.70 versus 5.31-8.70 U/mL, P < 0.01). Women with high-grade serous ovarian carcinoma had higher A2160 levels compared to other histologies (6.60 versus 3.01 U/mL, P = 0.05). Women who had suboptimal cytoreduction had significantly higher A2160 levels than those who achieved optimal/complete cytoreduction (7.02 versus 2.30-3.17 U/mL, P < 0.01). On univariable analysis, higher A2160 levels were significantly associated with decreased progression-free survival (64-100 versus 1-33%ile, 5-year rates 53.4 versus 78.9%, P = 0.029). After controlling for age, CA-125 level, cytoreductive status, histology, and stage, higher A2160 levels remained an independent prognostic factor for decreased progression-free survival (adjusted-hazard ratio (HR) 2.48, 95% confidence interval (CI) 1.01-6.11, P = 0.049). Similarly, higher A2160 levels were independently associated with decreased cause-specific survival on multivariable analysis (adjusted-HR 3.07, 95% CI 1.19-7.93, P = 0.021).

CONCLUSION:

Our study suggests that A2160 may be a useful prognostic biomarker for epithelial ovarian cancer, and higher pretreatment levels of A2160 predicts poor survival outcome.

KEYWORDS:

Biomarker; Complement 4-binding protein; Epithelial ovarian carcinoma; Full sialylation; Liquid chromatography–mass spectrometry; Survival

PMID:
29340789
DOI:
10.1007/s00404-018-4658-z
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center